PCNA degradation exhibits superior pharmacological effects over stoichiometric inhibition.

In this issue of Cell Chemical Biology, Chang et al. report that a PCNA-targeting bioPROTAC, an engineered E3 ligase linked to a PCNA-binding peptide, has superior pharmacological effects over inhibition of PCNA. Their findings demonstrate the feasibility of translating bioPROTACs from a concept to a candidate therapeutic modality.